Nothing Special   »   [go: up one dir, main page]

HRP20190742T1 - Nova anti-cd38 protutijela za liječenje raka - Google Patents

Nova anti-cd38 protutijela za liječenje raka Download PDF

Info

Publication number
HRP20190742T1
HRP20190742T1 HRP20190742TT HRP20190742T HRP20190742T1 HR P20190742 T1 HRP20190742 T1 HR P20190742T1 HR P20190742T T HRP20190742T T HR P20190742TT HR P20190742 T HRP20190742 T HR P20190742T HR P20190742 T1 HRP20190742 T1 HR P20190742T1
Authority
HR
Croatia
Prior art keywords
bis
benzodiazepine
tetrahydro
antibody
pyrrolo
Prior art date
Application number
HRP20190742TT
Other languages
English (en)
Inventor
Peter U Park
Laura M. Bartle
Anna Skaletskaya
Viktor S. Golmakher
Daniel Tavares
Jutta Deckert
Vincent Mikol
Véronique Blanc
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190742(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20190742T1 publication Critical patent/HRP20190742T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)

Claims (23)

1. Protutijelo koje specifično veže CD38, naznačeno time što: i. je navedeno protutijelo sposobno ubiti CD38+ stanicu apoptozom, stanično-posredovanom citotoksičnošću ovisnom o protutijelu (ADCC), i komplementarno ovisnom citotoksičnošću (CDC); ii. navedeno protutijelo sadrži barem jedan teški lanac, barem jedan laki lanac i barem jednu ljudsku konstantnu regiju; iii. navedeni teški lanac sadrži varijabilnu regiju koja ima sekvencu aminokiseline prema SEQ ID No.66; i iv. navedeni laki lanac sadrži varijabilnu regiju koja ima sekvencu aminokiseline prema SEQ ID No.62.
2. Protutijelo prema zahtjevu 1, naznačeno time što je navedeno protutijelo sposobno ubiti navedenu CD38+ stanicu apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome.
3. Protutijelo prema zahtjevu 1 ili 2, naznačeno time što navedena CD38+ stanica je stanica limfoma, stanica leukemije, ili stanica multiplog mijeloma.
4. Protutijelo prema zahtjevu 3, naznačeno time što navedena CD38+ stanica je stanica ne-Hodgkinovog limfoma (NHL), stanica Burkittovog limfoma (BL), stanica multiplog mijeloma (MM), stanica B kronične limfocitne leukemije (B-CLL), stanica B i T akutne limfocitne leukemije (ALL), stanica T-staničnog limfoma (TCL), stanica akutne mijeloične leukemije (AML), stanica leukemije vlasastih stanica (HCL), stanica Hodgkinovog limfoma (HL), ili stanica kronične mijeloične leukemije (CML).
5. Protutijelo prema zahtjevu 1, naznačeno time što: • navedeno protutijelo je sposobno ubiti barem 24 % Daudijevih stanica limfoma apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 7 % Ramosovih stanica limfoma apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 11 % MOLP-8 stanica multiplog mijeloma apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 36 % SU-DHL-8 stanica limfoma apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 62 % DND-41 stanica leukemije apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 27 % NU-DUL-1 stanica limfoma apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 9 % JVM-13 stanica leukemije apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome; i/ili • navedeno protutijelo je sposobno ubiti više od 4 % HC-1 stanica leukemije apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome.
6. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time što navedeno protutijelo veže CD38 s kD od 3 x 10-9 M ili nižim.
7. Protutijelo prema bilo kojem od zahtjeva 1 do 6, naznačeno time što navedeno protutijelo je humanizirano ili presvučeno protutijelo.
8. Protutijelo prema bilo kojem od zahtjeva 1 do 7, naznačeno time što navedena ljudska konstantna regija je ljudska IgG1/Kapa konstantna regija.
9. Konjugat koji sadrži protutijelo prema bilo kojem od zahtjeva 1 do 8 vezano na citotoksično sredstvo.
10. Konjugat prema zahtjevu 9, naznačen time što je navedeno citotoksično sredstvo odabrano iz skupine koja sadrži majtanzinoid, mali lijek, derivat tomajmicina, derivat leptomicina, predlijek, taksoid, CC-1065 i analog CC-1065.
11. Konjugat prema zahtjevu 10, naznačen time što: • navedeno citotoksično sredstvo je majtanzin DM1 s formulom: ili • navedeno citotoksično sredstvo je majtanzin DM4 s formulom : ili • navedeno citotoksično sredstvo je derivat tomajmicina odabran iz skupine koja sadrži: ∘ 8,8'-[1,3-benzendiilbis(metilenoksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-metoksi-1,3-benzendiilbis(metilenoksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[1,5-pentandiilbis(oksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-piroio[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[1,4-butanediilbis(oksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[3-metil-1,5-pentandiilbis(oksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[2,6-piridinediilbis(oksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[4-(3-tert-butoksikarbonilaminopropiloksi)-2,6-piridinediilbis-(metilenoksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-(3-aminopropiloksi)-1,3-benzendiilbis(metilenoksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-(N-metil-3-tert-butoksikarbonilaminopropil)-1,3-benzendiilbis-(metilenoksi)]-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-{5-[3-(4-metil-4-metildisulfanil-pentanoilamino)propiloksi]-1,3-benzendiilbis(metilenoksi)}-bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-acetiltiometil-1,3-benzendiilbis(metilenoksi)]-bis[(S)-2-metilen-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ tert-butil ester bis-[2-[(S)-2-metilen-7-metoksi-5-okso-1,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-8-iloksi]-etil}-karbaminske kiseline ∘ 8,8'-[3-(2-acetiltioetil)-1,5-pentandiilbis(oksi)]-bis[(S)-2-metilen-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-(N-4-merkapto-4,4-dimetilbutanoil)amino-1,3-benzendiilbis(metilenoksi)]-bis[7-metoksi-2-metilen-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-(N-4-metilditio-4,4-dimetilbutanoil)-amino-1,3-benzendiilbis(metilenoksi)]-bis[7-metoksi-2-metilen-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-(N-metil-N-(2-merkapto-2,2-dimetiletil)amino-1,3-benzendiil(metilenoksi)]-bis[7-metoksi-2-metilen-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[5-(N-metil-N-(2-metilditio-2,2-dimetiletil)amino-1,3-benzendiil(metilenoksi)]-bis[7-metoksi-2-metilen-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(2-(4-merkapto-4-metil)-pentanamido-etoksi)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(1-(2-(4-metil-4-metildisulfanil)-pentanamido-etoksi)-benzen-3,5-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(3-(4-metil-4-metildisulfanil)-pentanamido-propoksi)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(4-(4-metil-4-metildisulfanil)-pentanamido-butoksi)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(3-[4-(4-metil-4-metildisulfanil-pentanoil)-piperazin-1-il]-propil)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(1-(3-[4-(4-metil-4-metildisulfanil-pentanoil)-piperazin-1-il]-propil)-benzen-3,5-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(2-{2-[2-(4-metil-4-metildisulfanil-pentanoilamino)-etoksi]-etoksi}-etoksi)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(1-(2-{2-[2-(2-{2-[2-(4-metil-4-metildisulfanil-pentanoilamino)-etoksi]-etoksi}-etoksi)-etoksi]-etoksi}-etoksi)-benzen-3,5-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(1-(2-f2-[2-(4-metil-4-metildisulfanil-pentanoilamino)-etoksi]-etoksi}-etoksi)-benzen-3,5-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(2-{2-[2-(2-{2-[2-(4-metil-4-metildisulfanil-pentanoilamino)-etoksi]-etoksi}-etoksi)-etoksi]-etoksi}-etoksi)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(1-(2-[metil-(2-metil-2-metildisulfanil-propil)-amino]-etoksi)-benzen-3,5-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(3-[metil-(4-metil-4-metildisulfanil-pentanoil)-amino]-propil)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(4-(3-[metil-(2-metil-2-metildisulfanil-propil)-amino]-propil)-piridin-2,6-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on] ∘ 8,8'-[(1-(4-metil-4-metildisulfanil)-pentanamido)-benzen-3,5-dimetil)-dioksi]-bis[(S)-2-et-(E)-iliden-7-dimetoksi-1,2,3,11a-tetrahidro-pirolo[2,1-c][1,4]benzodiazepin-5-on], ili • navedeno citotoksično sredstvo je derivat leptomicina odabran iz skupine koju čine: ∘ (2-Metilsulfanil-etil)-amid (2E,10E,12E,16Z,18E)-(R)-6-Hidroksi-3,5, 7,9,11,15,17-heptametil-19-((2S,3S)-3-metil-6-okso-3,6-dihidro-2H-piran-2-il)-8-okso-nonadeka-2,10,12,16,18-pentaenske kiseline ∘ Bis-[(2-merkaptoetil)-amid (2E,10E,12E,16Z,18E)-(R)-6-hidroksi-3,5,7,9, 11,15,17-heptametil-19-((2S,3S)-3-metil-6-okso-3,6-dihidro-2H-piran-2-il)-8-okso-nonadeka-2,10,12,16,18-pentaenske kiseline] ∘ (2-Merkapto-etil)-amid (2E,10E,12E,16Z,18E)-(R)-6-hidroksi-3,5,7,9,11, 15,17-heptametil-19-((2S,3S)-3-metil-6-okso-3,6-dihidro-2H-piran-2-il)-8-okso-nonadeka-2,10,12,16,18-pentaenske kiseline ∘ (2-Metildisulfanil-etil)-amid (2E,10E,12E,16Z,18E)-(R)-6-hidroksi-3,5,7,9,11,15,17-heptametil-19-((2S,3S)-3-metil-6-okso-3,6-dihidro-2H-piran-2-il)-8-okso-nonadeka-2,10,12,16,18-pentaenske kiseline ∘ (2-Metil-2-metildisulfanil-propil)-amid (2E,10E,12E,16Z,18E)-(R)-6-hidroksi-3,5,7,9,11,15,17-heptametil-19-((2S,3S)-3-metil-6-okso-3,6-dihidro-2H-piran-2-il)-8-okso-nonadeka-2,10,12,16,18-pentaenske kiseline ∘ (2-Merkapto-2-metil-propil)-amid (2E,10E,12E,16Z,18E)-(R)-6-hidroksi-3,5,7,9,11,15,17-heptametil-19-((2S,3S)-3-metil-6-okso-3,6-dihidro-2H-piran-2-il)-8-okso-nonadeka-2,10,12,16,18-pentaenske kiseline.
12. Protutijelo prema bilo kojem od zahtjeva 1-8, ili konjugat prema bilo kojem od zahtjeva 9-11, naznačeno time što je za uporabu kao lijek.
13. Farmaceutski pripravak naznačen time što sadrži protutijelo prema bilo kojem od zahtjeva 1-8, ili konjugat prema bilo kojem od zahtjeva 9-11, te farmaceutski prihvatljiv nosač ili pomoćne tvari.
14. Farmaceutski pripravak prema zahtjevu 13, naznačen time što navedeni pripravak sadrži daljnje terapijsko sredstvo.
15. Farmaceutski pripravak prema zahtjevu 14, naznačen time što daljnje terapijsko sredstvo je antagonist epidermalnog faktora rasta (EGF), faktora rasta fibroblasta (FGF), faktora rasta hepatocita (HGF), tkivnog faktora (TF), proteina C, proteina S, faktora rasta izvedenog iz trombocita (PDGF), heregulina, makrofag stimulirajućeg proteina (MSP) ili vaskularnog endotelnog faktora rasta (VEGF), ili antagonist receptora za epidermalni faktor rasta (EGF), faktora rasta fibroblasta (FGF), faktora rasta hepatocita (HGF), tkivnog faktora (TF), proteina C, proteina S, faktora rasta izvedenog iz trombocita (PDGF), heregulina, makrofag stimulirajućeg proteina (MSP), ili vaskularnog endotelnog faktora rasta (VEGF), uključujući receptor HER2, receptor HER3, c-MET, i druge receptore tirozin kinaza; ili navedeno daljnje terapeutsko sredstvo je protutijelo usmjereno protiv klastera diferencijacijskog antigena odabranog iz skupine koja sadrži CD3, CD14, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD36, CD40, CD44, CD52, CD55, CD59, CD56, CD70, CD79, CD80, CD103, CD134, CD137, CD138, i CD152.
16. Protutijelo prema bilo kojem od zahtjeva 1-8, ili konjugat prema bilo kojem od zahtjeva 9-11, naznačeno time što je za uporabu za liječenje raka ili autoimune bolesti.
17. Protutijelo ili konjugat za uporabu prema zahtjevu 16, naznačeno time što navedeni rak je multipli mijelom.
18. Protutijelo ili konjugat za uporabu prema zahtjevu 16 naznačeno time što navedeni rak je limfom B-stanica.
19. Protutijelo ili konjugat za uporabu prema bilo kojem od zahtjeva 16 do 18, naznačeno time što liječenje nadalje obuhvaća uporabu daljnjeg terapeutskog sredstva u istom ili u drugom pripravku.
20. Protutijelo ili konjugat za uporabu prema zahtjevu 19, naznačeno time što daljnje terapijsko sredstvo je antagonist faktora rasta fibroblasta (FGF), faktora rasta hepatocita (HGF), tkivnog faktora (TF), proteina C, proteina S, faktora rasta izvedenog iz trombocita (PDGF), heregulina, makrofag stimulirajućeg proteina (MSP) ili vaskularnog endotelnog faktora rasta (VEGF), ili antagonist receptora za epidermalni faktor rasta (EGF), faktora rasta fibroblasta (FGF), faktora rasta hepatocita (HGF), tkivnog faktora (TF), proteina C, proteina S, faktora rasta izvedenog iz trombocita (PDGF), heregulina, makrofag stimulirajućeg proteina (MSP), ili vaskularnog endotelnog faktora rasta (VEGF), uključujući receptor HER2, receptor HER3, c-MET, i druge receptore tirozin kinaza; ili navedeno daljnje terapeutsko sredstvo je protutijelo usmjereno protiv klastera diferencijacijskog antigena odabranog iz skupine koja sadrži CD3, CD14, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD36, CD40, CD44, CD52, CD55, CD59, CD56, CD70, CD79, CD80, CD103, CD134, CD137, CD138, i CD152.
21. Polinukleotid naznačen time što: • navedeni polinukleotid kodira protutijelo kako je definirano u bilo kojem od patentnih zahtjeva 1-8; ili • navedeni polinukleotid kodira teški lanac i laki lanac protutijela tijela kako je definirano u bilo kojem od patentnih zahtjeva 1-8.
22. Rekombinantni vektor naznačen time što sadrži polinukleotid prema zahtjevu 21.
23. Stanica domaćin naznačena time što sadrži vektor prema zahtjevu 22.
HRP20190742TT 2006-10-19 2019-04-18 Nova anti-cd38 protutijela za liječenje raka HRP20190742T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291628A EP1914242A1 (en) 2006-10-19 2006-10-19 Novel anti-CD38 antibodies for the treatment of cancer
EP07859236.7A EP2076540B1 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer
PCT/IB2007/004172 WO2008047242A2 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
HRP20190742T1 true HRP20190742T1 (hr) 2019-06-14

Family

ID=37831721

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190742TT HRP20190742T1 (hr) 2006-10-19 2019-04-18 Nova anti-cd38 protutijela za liječenje raka

Country Status (45)

Country Link
US (5) US8153765B2 (hr)
EP (4) EP1914242A1 (hr)
JP (2) JP5607364B2 (hr)
KR (5) KR101534452B1 (hr)
CN (1) CN101616933B (hr)
AR (1) AR063488A1 (hr)
AU (1) AU2007311511C1 (hr)
BR (1) BRPI0718130B1 (hr)
CA (2) CA2663209C (hr)
CL (3) CL2007002995A1 (hr)
CO (1) CO6190555A2 (hr)
CR (1) CR10679A (hr)
CY (2) CY1122302T1 (hr)
DK (1) DK2076540T3 (hr)
DO (1) DOP2017000177A (hr)
EA (1) EA025215B1 (hr)
ES (1) ES2726754T3 (hr)
FR (1) FR20C1061I2 (hr)
GT (1) GT200900079A (hr)
HK (1) HK1139956A1 (hr)
HR (1) HRP20190742T1 (hr)
HU (2) HUE043351T2 (hr)
IL (1) IL197217B (hr)
LT (2) LT2076540T (hr)
MA (1) MA30895B1 (hr)
ME (1) MEP10609A (hr)
MX (1) MX2009004050A (hr)
MY (1) MY159374A (hr)
NL (1) NL301077I2 (hr)
NO (3) NO345911B1 (hr)
NZ (1) NZ575188A (hr)
PE (1) PE20081171A1 (hr)
PH (1) PH12012502467A1 (hr)
PL (1) PL2076540T3 (hr)
PT (1) PT2076540T (hr)
RS (1) RS58716B1 (hr)
SG (4) SG10202012950TA (hr)
SI (1) SI2076540T1 (hr)
SV (1) SV2009003203A (hr)
TN (1) TN2009000058A1 (hr)
TW (4) TWI609884B (hr)
UA (1) UA114879C2 (hr)
UY (1) UY30655A1 (hr)
WO (1) WO2008047242A2 (hr)
ZA (1) ZA200901395B (hr)

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
WO2006122355A1 (en) * 2005-05-16 2006-11-23 Qrsciences Pty Ltd A system and method for improving the analysis of chemical substances using nqr
CA2621982C (en) 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
DK2019104T3 (da) 2007-07-19 2013-12-16 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
JP5680671B2 (ja) 2009-12-22 2015-03-04 ロシュ グリクアート アーゲー 抗ｈｅｒ３抗体及びその使用
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
US9220743B2 (en) * 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
LT2580243T (lt) 2010-06-09 2020-01-27 Genmab A/S Antikūnai prieš žmogaus cd38
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
AU2011310696B2 (en) 2010-09-27 2016-06-02 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
KR101942237B1 (ko) * 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
EP2691155B1 (en) 2011-03-29 2018-11-14 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
WO2012143499A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
BR112014006703A8 (pt) 2011-09-20 2018-01-09 Spirogen Sarl "pirrolobenzodiazepinas
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
EA027386B1 (ru) 2011-10-14 2017-07-31 Медимьюн Лимитед Пирролобензодиазепины
EP3309162A1 (en) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Targeted conjugates of pyrrolobenzodiazepines
CA2850103C (en) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
MX360741B (es) 2011-10-28 2018-11-14 Teva Pharmaceuticals Australia Pty Ltd Constructos de polipéptidos y sus usos.
WO2013075740A1 (en) * 2011-11-23 2013-05-30 Sanofi Antibody purification method
CN108324943B (zh) * 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
SG11201407106XA (en) 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
CA2873889A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Anti-cd22 antibodies and immunoconjugates
US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
BR112015006731A2 (pt) 2012-09-25 2017-07-04 Morphosys Ag combinações e usos das mesmas
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
TR201910662T4 (tr) 2012-10-12 2019-08-21 Medimmune Ltd Pirrolobenzodiazepinler ve bunlara ait konjugatlar.
EP2906253B9 (en) 2012-10-12 2019-02-27 ADC Therapeutics SA Pyrrolobenzodiazepine - anti-psma antibody conjugates
TR201902494T4 (tr) 2012-10-12 2019-03-21 Medimmune Ltd Pirrolobenzodiazepinler ve onların konjugatları.
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2014057072A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
SMT201800010T1 (it) 2012-10-12 2018-03-08 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo anti-cd22
LT2906296T (lt) 2012-10-12 2018-06-11 Adc Therapeutics Sa Pirolobenzodiazepino-antikūno konjugatai
US9624308B2 (en) 2012-11-05 2017-04-18 Pierre Fabre Medicament Antigen binding proteins
WO2014068114A1 (en) 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
CN112043826A (zh) 2013-03-13 2020-12-08 赛诺菲 包含抗cd38抗体和卡非佐米的组合物
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
AR096287A1 (es) 2013-03-13 2015-12-23 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP6436965B2 (ja) 2013-03-14 2018-12-12 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及びイムノコンジュゲート
EP3677591B1 (en) 2013-04-29 2022-12-28 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
DK2994485T3 (en) * 2013-05-06 2018-04-23 Sanofi Sa CONTINUOUS MULTIPLE STEP PROCEDURE FOR PURIFICATION OF ANTIBODIES
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
JP2016537399A (ja) 2013-09-17 2016-12-01 ジェネンテック， インコーポレイテッド 抗ｌｇｒ５抗体を使用する方法
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
JP2016536314A (ja) * 2013-10-31 2016-11-24 サノフイ ヒトのがんを治療するための特異的抗ｃｄ３８抗体
SG10201909806SA (en) 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
CA2931340A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
HUE041497T2 (hu) 2014-02-14 2019-05-28 Cellectis Immunsejteken és patológiás sejteken egyaránt jelen lévõ antigént célzó génmódosított sejtek immunterápia célra
EP3104882B1 (en) * 2014-02-14 2019-06-05 Centrose, Llc Extracellular targeted drug conjugates
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2775431T3 (es) * 2014-03-28 2020-07-27 Xencor Inc Anticuerpos biespecíficos que se unen a CD38 y CD3
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
WO2015195556A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
KR102615681B1 (ko) 2014-08-28 2023-12-18 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
US20160067205A1 (en) * 2014-09-09 2016-03-10 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
CN113698485A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
EP3193931B1 (en) * 2014-09-16 2020-08-05 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
MA55043A (fr) 2014-11-26 2021-12-29 Xencor Inc Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2969717A1 (en) * 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
RS61668B1 (sr) 2015-05-13 2021-04-29 Morphosys Ag Lečenje multiplog mijeloma (mm)
CA2986594A1 (en) 2015-05-20 2016-11-24 Tufts Medical Center, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
FI3303396T3 (fi) 2015-05-29 2023-02-22 Vasta-aineita ox40:ää vastaan ja niiden käyttöjä
SMT202000226T1 (it) 2015-05-30 2020-05-08 Molecular Templates Inc Impalcatura di subunita' a della tossina shiga de-immunizzate e molecole di targeting cellulare comprendenti la stessa
EA036789B1 (ru) 2015-06-22 2020-12-22 Янссен Байотек, Инк. Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
BR112017027813A2 (pt) 2015-06-22 2018-08-28 Bayer Pharma Aktiengesellschaft conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis
AU2016281717B2 (en) 2015-06-24 2022-07-28 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
US10746739B2 (en) * 2015-09-14 2020-08-18 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating RhoH
CA2996205A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) * 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
CN105837688B (zh) * 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
TWI717432B (zh) 2015-12-02 2021-02-01 美商艾吉納斯公司 抗體和使用彼之方法
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
CN113817060B (zh) * 2016-01-09 2024-03-08 嘉立医疗科技(广州)有限公司 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11618789B2 (en) 2016-03-04 2023-04-04 Morphosys Ag Clinical assessment of M-protein response in multiple myeloma
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
BR112018069483A2 (pt) 2016-03-24 2019-07-30 Bayer Pharma AG pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR20200087875A (ko) 2016-04-15 2020-07-21 바이오아트라, 엘엘씨 항 Axl항체 및 이의 면역접합체와 이것들의 용도
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
TW202434312A (zh) 2016-05-13 2024-09-01 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
EP3474895A1 (en) * 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2018013917A1 (en) * 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
EP3487522A4 (en) 2016-07-19 2020-04-01 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
US10478497B2 (en) * 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
EP3494135A1 (en) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US11697680B2 (en) 2016-11-21 2023-07-11 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018217926B2 (en) 2017-02-08 2019-10-03 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
AU2018253948B2 (en) 2017-04-20 2024-08-01 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
EP3635002A1 (en) 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
CN110997009B (zh) * 2017-06-20 2025-01-21 索伦托药业有限公司 Cd38抗体药物缀合物
MX2019015841A (es) 2017-06-20 2020-08-03 Inst Curie Celulas inmunes defectuosas para suv39h1.
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US20200121815A1 (en) 2017-07-31 2020-04-23 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
ES2911243T3 (es) * 2017-08-10 2022-05-18 Grifols Diagnostic Solutions Inc Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7299873B2 (ja) 2017-08-16 2023-06-28 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８抗体
EP3668896A1 (en) * 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 modulating antibody
ES2906965T3 (es) 2017-08-18 2022-04-21 Medimmune Ltd Conjugados de pirrolobenzodiazepina
CN111133007A (zh) 2017-09-13 2020-05-08 特尼奥生物股份有限公司 与胞外酶结合的重链抗体
US20200255526A1 (en) * 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN116999572A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物、药物组合物及其在制备治疗肿瘤的药物中的应用
KR20200058540A (ko) * 2017-10-02 2020-05-27 비스테라, 인크. Cd138에 대한 항체 분자 및 이의 용도
MX2020004129A (es) * 2017-10-10 2020-08-20 Sanofi Sa Anticuerpos anti-cd38 y metodos de uso.
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
MX2020004243A (es) 2017-11-01 2020-09-25 Juno Therapeutics Inc Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
MA51105A (fr) 2017-12-08 2020-10-14 Juno Therapeutics Inc Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
MA51114A (fr) 2017-12-08 2020-10-14 Juno Therapeutics Inc Procédé de production d'une compositions de lymphocytes t modifiés
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN110144008B (zh) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
US11555070B2 (en) * 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途
AU2019301283B2 (en) * 2018-07-10 2024-12-19 Sanofi Combination therapies against cancer targeting CD38 and TGF-beta
CA3105694A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
PE20211858A1 (es) 2018-07-13 2021-09-21 Genmab As Variantes de anticuerpos anti-cd38 y sus usos
CN112585163A (zh) 2018-08-08 2021-03-30 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
CN112805378A (zh) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 用于评估整合核酸的方法
US20220275100A1 (en) 2018-09-11 2022-09-01 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
CN109293773B (zh) * 2018-09-25 2020-09-04 上海邦耀生物科技有限公司 靶向cd38蛋白的抗体、嵌合抗原受体和药物
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CA3116878A1 (en) 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
MX2021004732A (es) 2018-10-26 2021-06-04 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd38.
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
MX2021005024A (es) 2018-11-01 2021-07-21 Juno Therapeutics Inc Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
MX2021005611A (es) 2018-11-13 2021-06-30 Janssen Biotech Inc Control de metales traza durante la produccion de anticuerpos anti-cd38.
EP3893841A1 (en) 2018-12-14 2021-10-20 MorphoSys AG Antibody formulations
CA3125484A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CN113784987B (zh) 2019-01-22 2024-09-13 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
BR112021014699A2 (pt) 2019-01-28 2021-11-23 Sanofi Sa Métodos de tratamento de mieloma múltiplo
EP3917952A4 (en) * 2019-01-28 2022-11-02 Multitude Inc. CD44-SPECIFIC ANTIBODIES
BR112021016923A2 (pt) 2019-02-27 2021-11-03 Genentech Inc Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
MX2021011181A (es) 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
TW202104269A (zh) 2019-04-23 2021-02-01 法商賽諾菲公司 抗ｃｄ３８抗體和調配物
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
MA55811A (fr) 2019-05-01 2022-03-09 Editas Medicine Inc Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés
MA55967A (fr) 2019-05-14 2022-03-23 Sanofi Sa Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
WO2021013950A1 (en) 2019-07-23 2021-01-28 Mnemo Therapeutics Immune cells defective for suv39h1
CN112538114A (zh) * 2019-09-20 2021-03-23 上海普铭生物科技有限公司 抗人cd38抗体及其应用
AU2020371628A1 (en) * 2019-10-21 2022-05-19 Purdue Research Foundation Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
CA3156761A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
MX2022005400A (es) 2019-11-06 2022-05-24 Genentech Inc Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
BR112022010905A2 (pt) 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea
EP4069740A1 (en) 2019-12-06 2022-10-12 Sanofi-Aventis U.S. LLC Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma
JP2023506158A (ja) 2019-12-12 2023-02-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
AU2020405183A1 (en) 2019-12-18 2022-06-09 TeneoFour, Inc. Heavy chain antibodies binding to CD38
PE20230113A1 (es) 2020-01-16 2023-01-27 Genmab As Formulaciones de anticuerpos anti-cd38 y usos de las mismas
MX2022012533A (es) 2020-04-10 2022-12-13 Juno Therapeutics Inc Metodos y usos relacionados con terapia celular dise?ada con un receptor de antigeno quimerico dirigido al antigeno de maduracion de celulas b.
AU2021259628A1 (en) * 2020-04-24 2023-01-05 Millennium Pharmaceuticals, Inc. Anti-CD19 antibodies and uses thereof
JP2023528215A (ja) 2020-05-13 2023-07-04 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
EP4171585A1 (en) 2020-06-26 2023-05-03 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
CN111808193B (zh) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 可结合人cd38的纳米抗体及其应用
CA3190266A1 (en) 2020-07-30 2022-02-03 Institut Curie Immune cells defective for socs1
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
JP2023541457A (ja) 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド Ｃｄ３８修飾のための化合物および方法
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN112300281B (zh) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 含有nk细胞的药物组合物及其治疗癌症的用途
CA3197381A1 (en) 2020-11-03 2022-05-12 Sanofi-Aventis U.S. Llc Use of isatuximab for the treatment of multiple myeloma
CN116802203A (zh) 2020-11-04 2023-09-22 朱诺治疗学股份有限公司 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
WO2022112469A1 (en) 2020-11-27 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
US20220202859A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
JP2024503432A (ja) 2021-01-14 2024-01-25 モルフォシス・アーゲー 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
EP4337763A1 (en) 2021-05-10 2024-03-20 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
TW202309077A (zh) 2021-05-12 2023-03-01 瑞士商Ｃｒｉｓｐｒ治療公司 用於治療實性瘤的靶向ｃｄ７０的基因工程化免疫細胞
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
CN113244175B (zh) * 2021-05-22 2022-11-04 苏州大学 一种免疫囊泡美登素偶联物及其制备方法与应用
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
CA3216228A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
CA3225405A1 (en) 2021-07-28 2023-02-02 Alexander Joachim Paul Ungewickell Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN113896802A (zh) * 2021-10-09 2022-01-07 宜明昂科生物医药技术（上海）有限公司 靶向cd47和cd38的重组融合蛋白及其制备和用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20230136301A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
CN113912727B (zh) * 2021-11-16 2023-05-02 福州迈新生物技术开发有限公司 抗cd38蛋白单克隆抗体、细胞系及其制备方法和应用
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
CN114457017B (zh) * 2022-01-19 2023-10-17 四川大学华西第二医院 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用
EP4469563A1 (en) 2022-01-28 2024-12-04 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023172917A1 (en) 2022-03-07 2023-09-14 Sanofi-Aventis U.S. Llc Use of isatuximab in combination with other agents for the treatment of multiple myeloma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
PE20242350A1 (es) 2022-05-03 2024-12-16 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024040151A1 (en) 2022-08-18 2024-02-22 Pfizer Inc. Sirp alpha fusion protein and anti-cd38 antibody combination therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024095173A1 (en) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Methods of treating cancers
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
US2429004A (en) 1947-02-20 1947-10-14 Wachsman Michael Fabric contacting circuit closer for knitting machines
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
CA1341411C (en) 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
EP0604647A4 (en) * 1992-07-16 1996-09-25 Icos Corp Alleviation of symptoms associated with inflammatory disease states.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE69907977T2 (de) 1998-08-27 2004-07-22 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
WO2001091793A1 (en) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
DK1553975T3 (da) 2002-09-27 2012-05-07 Xencor Inc Optimerede Fc-varianter og fremgangsmåder til generering heraf.
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
NZ539395A (en) 2002-11-07 2009-01-31 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
US20050208627A1 (en) * 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
JPWO2005035741A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
CA2543318C (en) 2003-10-22 2013-01-08 B. Rao Vishnuvajjala Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
JP2008504013A (ja) * 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
WO2005085260A1 (en) 2004-03-09 2005-09-15 Spirogen Limited Pyrrolobenzodiazepines
KR100891620B1 (ko) * 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
US7850962B2 (en) * 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7527973B2 (en) * 2004-06-21 2009-05-05 Washington University Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
AU2005270918B2 (en) * 2004-08-03 2011-03-03 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
DK1853718T3 (en) * 2005-02-15 2015-11-09 Univ Duke ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
EP1866338B1 (en) * 2005-03-23 2016-09-21 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US20090123950A1 (en) * 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
DE102005030112A1 (de) 2005-06-28 2007-01-18 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Lötzusatzwerkstoff
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
PL1813614T3 (pl) 2006-01-25 2012-03-30 Sanofi Sa Środki cytotoksyczne zawierające nowe pochodne tomaymycyny
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EA201100228A1 (ru) * 2008-07-21 2011-08-30 Иммьюномедикс, Инк. Структурные варианты антител для улучшения терапевтических характеристик
AU2011310696B2 (en) * 2010-09-27 2016-06-02 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX360741B (es) * 2011-10-28 2018-11-14 Teva Pharmaceuticals Australia Pty Ltd Constructos de polipéptidos y sus usos.
KR101515894B1 (ko) 2012-02-20 2015-05-19 주식회사 노리코리아 지식 유닛에 기초하여 교육 서비스를 제공하기 위한 방법, 시스템 및 컴퓨터 판독 가능한 기록 매체
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US20160067205A1 (en) * 2014-09-09 2016-03-10 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies
CA2969717A1 (en) * 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
CN107111564B (zh) * 2015-01-06 2020-11-06 惠普发展公司有限责任合伙企业 用于对连接器进行串接的适配器
CA2986594A1 (en) * 2015-05-20 2016-11-24 Tufts Medical Center, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
EA036789B1 (ru) * 2015-06-22 2020-12-22 Янссен Байотек, Инк. Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) * 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) * 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
MX2020004129A (es) * 2017-10-10 2020-08-20 Sanofi Sa Anticuerpos anti-cd38 y metodos de uso.
US11605302B2 (en) 2020-11-10 2023-03-14 Rockwell Collins, Inc. Time-critical obstacle avoidance path planning in uncertain environments

Also Published As

Publication number Publication date
BRPI0718130A2 (pt) 2013-11-05
SG10201501733QA (en) 2015-04-29
EP3498735A1 (en) 2019-06-19
PT2076540T (pt) 2019-06-06
WO2008047242A3 (en) 2008-06-26
CA2663209A1 (en) 2008-04-24
CL2017001580A1 (es) 2018-03-02
ME00614B (me) 2011-12-20
UY30655A1 (es) 2008-05-31
TW201518322A (zh) 2015-05-16
NO20091712L (no) 2009-05-13
TWI609885B (zh) 2018-01-01
NO345911B1 (no) 2021-10-11
CA2663209C (en) 2018-02-13
KR101800328B1 (ko) 2017-11-22
CN101616933B (zh) 2015-06-10
PL2076540T3 (pl) 2019-08-30
KR101534452B1 (ko) 2015-07-06
SG174777A1 (en) 2011-10-28
FR20C1061I1 (hr) 2021-01-22
AU2007311511C1 (en) 2021-11-04
CY2020039I2 (el) 2021-05-05
SV2009003203A (es) 2009-10-27
LTPA2020536I1 (lt) 2020-12-28
JP2014221761A (ja) 2014-11-27
PE20081171A1 (es) 2008-09-26
CA2989609A1 (en) 2008-04-24
JP2010506582A (ja) 2010-03-04
ES2726754T3 (es) 2019-10-09
CY1122302T1 (el) 2021-01-27
KR101852317B1 (ko) 2018-04-25
NL301077I1 (hr) 2020-12-02
CO6190555A2 (es) 2010-08-19
KR20140105035A (ko) 2014-08-29
AU2007311511B9 (en) 2020-11-12
HUS2000048I1 (hu) 2020-12-28
KR20150119976A (ko) 2015-10-26
AU2007311511B2 (en) 2013-08-22
MX2009004050A (es) 2009-04-28
TN2009000058A1 (en) 2010-08-19
MA30895B1 (fr) 2009-11-02
CL2012002012A1 (es) 2012-11-05
HK1139956A1 (en) 2010-09-30
UA114879C2 (uk) 2017-08-28
EA025215B1 (ru) 2016-12-30
CR10679A (es) 2009-06-24
EP1914242A1 (en) 2008-04-23
IL197217B (en) 2019-12-31
EP3909980A1 (en) 2021-11-17
EP2076540B1 (en) 2019-02-27
MY159374A (en) 2016-12-30
US20110262454A1 (en) 2011-10-27
NL301077I2 (nl) 2021-02-03
NO20211026A1 (no) 2009-05-13
TW201734053A (zh) 2017-10-01
EP2076540A2 (en) 2009-07-08
NZ575188A (en) 2012-07-27
AU2007311511A1 (en) 2008-04-24
KR20150023010A (ko) 2015-03-04
SG10202012950TA (en) 2021-02-25
CN101616933A (zh) 2009-12-30
US20200408765A1 (en) 2020-12-31
WO2008047242A9 (en) 2009-02-05
MEP10609A (hr) 2011-12-20
DK2076540T3 (da) 2019-05-13
KR20170129960A (ko) 2017-11-27
WO2008047242A2 (en) 2008-04-24
EA200970393A1 (ru) 2009-12-30
US20170343550A1 (en) 2017-11-30
WO2008047242A8 (en) 2009-08-06
US8153765B2 (en) 2012-04-10
CL2007002995A1 (es) 2008-05-16
RS58716B1 (sr) 2019-06-28
TW200823236A (en) 2008-06-01
KR20090078330A (ko) 2009-07-17
LT2076540T (lt) 2019-06-10
IL197217A0 (en) 2011-08-01
JP6121366B2 (ja) 2017-04-26
US20120156218A1 (en) 2012-06-21
AR063488A1 (es) 2009-01-28
BRPI0718130B1 (pt) 2022-05-03
NO2021044I1 (no) 2021-10-13
SI2076540T1 (sl) 2019-06-28
TWI609884B (zh) 2018-01-01
TWI538917B (zh) 2016-06-21
US20090304710A1 (en) 2009-12-10
CY2020039I1 (el) 2021-03-12
GT200900079A (es) 2010-07-09
TW201630938A (zh) 2016-09-01
ZA200901395B (en) 2010-06-30
DOP2017000177A (es) 2017-09-15
SG173345A1 (en) 2011-08-29
HUE043351T2 (hu) 2019-08-28
FR20C1061I2 (fr) 2022-02-11
JP5607364B2 (ja) 2014-10-15
NO348288B1 (no) 2024-11-11
PH12012502467A1 (en) 2013-06-17

Similar Documents

Publication Publication Date Title
HRP20190742T1 (hr) Nova anti-cd38 protutijela za liječenje raka
JP7173971B2 (ja) 抗ＳＩＲＰ－α抗体及びその使用方法
AU2020264364B2 (en) Novel anti-cd38 antibodies for the treatment of cancer
CN109535253B (zh) 新型抗cd19抗体
CA3142021A1 (en) Humanized antibody molecules to cd138 and uses thereof
CA3147887A1 (en) Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas
RU2791445C2 (ru) Новые анти-cd19-антитела
RU2021137832A (ru) Анти-ror1/анти-cd3 биспецифические связывающие молекулы
TW202500591A (zh) 新型抗cd19抗體